Tumor vaccines and beyond

Cytotherapy

Volumn 13, Issue 1, 2011, Pages 8-18

  Melenhorst, Jan Joseph ^a   Barrett, Austin John ^a  

^a Hematology Branch   (United States)

Author keywords

Cancer vaccines; Gene therapy; Genes; Stem cell transplantation; T cell receptor

Indexed keywords

ARGINASE; B7 ANTIGEN; CANCER VACCINE; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD28 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; DNA; GAMMA INTERFERON; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; LEUKOCYTE ELASTASE INHIBITOR; LIVER RECEPTOR HOMOLOG 1; MELAN A; MYELOBLASTIN; RECOMBINANT INTERLEUKIN 2; RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; WT1 PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BLOOD SAMPLING; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL PROLIFERATION; COLON CARCINOMA; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKEMIA; LEUKEMIA CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

EID: 78650312241     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.530649     Document Type: Review

References (163)

1. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008;105:4283-8.
2. Fialkow P, Singer J, Adamson J, Vaidya K, Dow L, Ochs J, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood. 1981;57:1068-73.
3. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317:468-73.
4. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science. 1987;238:193-7.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectaltumor development. N Engl J Med. 1988;319:525-32.
6. Tsao JL, Yatabe Y, Salovaara R, Jarvinen HJ, Mecklin JP, Aaltonen LA, et al. Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci USA. 2000;97: 1236-41.
7. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol. 1999;9:M57-60.
8. Battegay M, Elzi L. Morbidity and mortality in HIV-infected individuals: a shift towards comorbidities. Swiss Med Wkly. 2009;139:564-70.
9. Ramirez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, Gonzalez-Lahoz J. [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc). 2009;133:729-35.
10. Marin-Muller C, Li M, Chen C, Yao Q. Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA). World J Surg. 2009;33:653-60.
11. Yarchoan R, Tosato G, Little RF. Therapy insight: AIDSrelated malignancies: the infl uence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol. 2005;2:406-15, 23.
12. Coulie PG, Ikeda H, Baurain JF, Chiari R. Antitumor immunity at work in a melanoma patient. Adv Cancer Res. 1999;76:213-42.
13. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478-88.
14. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infi ltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676-80.
15. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia: defi nition of leukemiaassociated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91:1653-61.
16. Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol. 2008;21:391-404.
17. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem. 2006;13:2345-52.
18. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol. 2006;18:599-604.
19. B oon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
20. Van den Eynde B, Van der Bruggen P. Peptide database of T cell defi ned tumor antigens. Academy of Cancer Immunology http://www.cancerimmunity.org/ peptidedatabase/Tcellepitopes. htm. 2010.
21. Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. Cancer Sci. 2007;98:1139-46.
22. Lucas S, Coulie PG. About human tumor antigens to be used in immunotherapy. Semin Immunol. 2008;20:301-7.
23. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specifi c for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450-7.
24. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specifi c for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997; 90:2529-34.
25. Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, et al. Identifi cation and in vitro expansion of CD4- and CD8- T cells specifi c for human neutrophil elastase. Blood. 2004;103:3076-83.
26. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, et al. In vitro induction of myeloid leukemia-specifi c CD4 and CD8 T cells by CD40 ligandactivated B cells gene modifi ed to express primary granule proteins. Clin Cancer Res. 2005;11:4495-503.
27. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specifi c T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-23.
28. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Gostick E, Ladell K, Roederer M, et al. High avidity myeloid leukemiaassociated antigen-specifi c CD8- T cells preferentially reside in the bone marrow. Blood. 2009;113:2238-44.
29. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Lissina A, Gostick E, Cole DK, et al. Detection of low avidity CD8(-) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods. 2008;338:31-9.
30. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specifi c T cells. J Clin Invest. 2003;111:639-47.
31. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89:1405-12.
32. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-9.
33. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, et al. Wilmstumour gene 1 (WT1) in human neoplasia. Leukemia. 2005;19:1318-23.
34. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-84.
35. Hubinger G, Schmid M, Linortner S, Manegold A, Bergmann L, Maurer U. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol. 2001;29:1226-35.
36. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, et al. Wilmstumor gene WT1-shRNA as a potent apoptosisinducing agent for solid tumors. Int J Oncol. 2008;32: 701-11.
37. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilmstumor gene WT1 in leukemias. Blood. 1996;87:2171-9.
38. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, et al. WT1 mutations in T-ALL. Blood. 2009; 114:1038-45.
39. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113:5951-60.
40. King-Underwood L, Pritchard-Jones K. Wilms tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998;91:2961-8.
41. Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;115:3719-27.
42. Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia. 2009;23:1472-9.
43. Barrett AJ, Melenhorst JJ. Minor histocompatibility antigen discovery: turning up the HEATR. Blood. 2010;115: 4630-1.
44. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-7.
45. Pierce RA, Field ED, Mutis T, Golovina TN, Von Kap-Herr C, Wilke M, et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol. 2001;167:3223-30.
46. Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensink E, et al. A human minor histocompatibility antigen specifi c for B cell acute lymphoblastic leukemia. J Exp Med. 1999;189:301-8.
47. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, Woestenenk R, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest. 2005;115:3506-16.
48. Spaapen RM, Lokhorst HM, van den Oudenalder K, Otterud BE, Dolstra H, Leppert MF, et al. Toward targeting B cell cancers with CD4- CTLs: identifi cation of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med. 2008;205:2863-72.
49. Bleakley M, Otterud BE, Richardt JL, Mollerup AD, Hudecek M, Nishida T, et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8- T cells. Blood. 2010;115:4923-33.
50. Spierings E, Gras S, Reiser JB, Mommaas B, Almekinders M, Kester MG, et al. Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele. J Immunol. 2009;182:4809-16.
51. Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008;118:1099-109.
52. Bannert N, Kurth R. The evolutionary dynamics of human endogenous retroviral families. Annu Rev Genomics Hum Genet. 2006;7:149-73.
53. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilmstumor gene)-specifi c cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885-90.
54. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specifi c T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008; 111:236-42.
55. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541-8.
56. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4- T cells are required for secondary expansion and memory in CD8- T lymphocytes. Nature. 2003;421:852-6.
57. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4- T-cell help controls CD8- T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88-93.
58. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003; 300:337-9.
59. Ryu SJ, Jung KM, Yoo HS, Kim TW, Kim S, Chang J, et al. Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specifi c dominant minor histocompatibility antigen, H60. Blood. 2009;113:4273-80.
60. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodefi cient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-41.
61. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-44.
62. Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, et al. Alloreactive CD4- T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol. 1996;93:606-12.
63. Faber LM, van Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH. Generation of CD4- cytotoxic Tlymphocyte clones from a patient with severe graft-versushost disease after allogeneic bone marrow transplantation: impli cations for graft-versus-leukemia reactivity. Blood. 1995;86:2821-8.
64. Dodi IA, Van Rhee F, Forde HC, Roura-Mir C, Jaraquemada D, Goldman JM, et al. CD4(-) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy. 2002;4:353-63.
65. Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, et al. CD4(-) cytotoxic T-cell clones specifi c for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specifi c and HLA-DR-restricted manner. Blood. 1998;92:3355-61.
66. Griffi oen M, van der Meijden ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SA, et al. Identifi cation of phosphatidylinositol 4-kinase type II beta as HLA class IIrestricted target in graft versus leukemia reactivity. Proc Natl Acad Sci USA. 2008;105:3837-42.
67. Nishimura M, Uchida S, Mitsunaga S, Yahagi Y, Nakajima K, Tadokoro K, et al. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4- and CD8- cytotoxic T-cell clones and tumor necrosis factor beta production by CD4- T-cell clones. Blood. 1997;89:1440-5.
68. Appay V. The physiological role of cytotoxic CD4(-) T-cells: the holy grail? Clin Exp Immunol. 2004;138:10-3.
69. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, et al. Acquisition of direct antiviral effector functions by CMV-specifi c CD4- T lymphocytes with cellular maturation. J Exp Med. 2006;203:2865-77.
70. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, et al. Direct recognition and lysis of leukemia cells by WT1- specifi c CD4- T lymphocytes in an HLA class II-restricted manner. Blood. 2005;106:1415-8.
71. Zorn E, Wang KS, Hochberg EP, Canning C, Alyea EP, Soiffer RJ, et al. Infusion of CD4- donor lymphocytes induces the expansion of CD8- donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002;8:2052-60.
72. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-43.
73. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, et al. Toxicity and effi cacy of defi ned doses of CD4(-) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91: 3671-80.
74. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. I. Vaccines for solid tumours. Lancet Oncol. 2004;5:681-9.
75. Mocellin S, Semenzato G, Mandruzzato S, Riccardo Rossi C. II. Vaccines for haematological malignant disorders. Lancet Oncol. 2004;5:727-37.
76. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA. 2004; 101(Suppl 2):14631-8.
77. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101:3142-9.
78. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738-43.
79. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-67.
80. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793-807.
81. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-5.
82. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195-204.
83. von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Jedema I, Mulder A, Willemze R, et al. Molecular persistence of chronic myeloid leukemia caused by donor T cells specifi c for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia. 2006;20:1040-6.
84. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904-8.
85. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, et al. Circulating tumor antigen-specifi c regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2007;104:20884-9.
86. Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009;15:2166-73.
87. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, et al. The CD4(-) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 2009;69:4335-45.
88. Jandus C, Bioley G, Dojcinovic D, Derre L, Baitsch L, Wieckowski S, et al. Tumor antigen-specifi c FOXP3- CD4 T cells identifi ed in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res. 2009;69:8085-93.
89. Lehe C, Ghebeh H, Al-Sulaiman A, Al Qudaihi G, Al- Hussein K, Almohareb F, et al. The Wilmstumor antigen is a novel target for human CD4- regulatory T cells: implications for immunotherapy. Cancer Res. 2008;68:6350-9.
90. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specifi c Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest. 2009;119:3311-21.
91. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4- T cells that facilitate tumor development. J Exp Med. 2007;204:1037-47.
92. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specifi c for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-85.
93. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al. Effector function of human tumor-specifi c CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64:2865-73.
94. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, et al. Lack of terminally differentiated tumor-specifi c CD8- T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003;63:2535-45.
95. Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA. 1986;83:6622-6.
96. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297:1867-70.
97. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3:1097-101.
98. Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Herve C, Li XL, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117:1096-106.
99. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002;168:3771-6.
100. Munn DH, Shafi zadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363-72.
101. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459-68.
102. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280-90.
103. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-3.
104. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-74.
105. Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia. 2007;21:353-5.
106. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618-31.
107. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identifi cation of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546-53.
108. Bronte V. Myeloid-derived suppressor cells in infl ammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol. 2009;39:2670-2.
109. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270-8.
110. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(-)CD25(-)Foxp3(-) T cells. Gastroenterology. 2008; 135:234-43.
111. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50:799-807.
112. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044-8.
113. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553-60.
114. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13:721-6s.
115. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14- HLA-DR low/ - monocytes in prostate cancer. Prostate. 2010;70:443-55.
116. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha- myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562-8.
117. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, et al. Population alterations of L:-arginase-and inducible nitric oxide synthase-expressed CD11b(-)/CD14 (-)/CD15 (-)/CD33 (-) myeloid-derived suppressor cells and CD8 (-) T lymphocytes in patients with advanced-stage nonsmall cell lung cancer. J Cancer Res Clin Oncol. 2009 Jul 2. [Epub ahead of print].
118. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14- HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70:4335-45.
119. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12-26.
120. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114-25.
121. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specifi c CD8 T cells infi ltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537-44.
122. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumorinfi ltrating CD8(-) T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389-95.
123. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infi ltrating NY-ESO-1-specifi c CD8- T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107:7875-80.
124. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-66.
125. Lee H, Kim JH, Yang SY, Kong J, Oh M, Jeong DH, et al. Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. J Cancer Res Clin Oncol. 2010;136:1445-52.
126. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol/Hematol (2010), doi:10.1016/j. critrevonc.2010.02.004.
127. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-75.
128. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139-47.
129. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. 2009;9:445-52.
130. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010;33:225-35.
131. Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y, et al. HapMap scanning of novel human minor histocompatibility antigens. Blood. 2009;113:5041-8.
132. Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer. 1992;50:289-97.
133. Carrasco J, Van Pel A, Neyns B, Lethe B, Brasseur F, Renkvist N, et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol. 2008;180:3585-93.
134. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specifi c antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA. 2001;98:10290-5.
135. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol. 2003; 171:4898-904.
136. van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005;23:9008-21.
137. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specifi c CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer. 1994;58:330-9.
138. Butterfi eld LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9:998-1008.
139. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptidebased vaccines. J Clin Oncol. 2002;20:2624-32.
140. Lally KM, Mocellin S, Ohnmacht GA, Nielsen MB, Bettinotti M, Panelli MC, et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer. 2001;93:841-7.
141. Chattopadhyay PK, Melenhorst JJ, Ladell K, Gostick E, Scheinberg P, Barrett AJ, et al. Techniques to improve the direct ex vivo detection of low frequency antigen-specifi c CD8- T cells with peptide-major histocompatibility complex class I tetramers. Cytometry A. 2008;73:1001-9.
142. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer- Williams MG, Bell JI, et al. Phenotypic analysis of antigenspecifi c T lymphocytes. Science. 1996;274:94-6.
143. Novak EJ, Liu AW, Nepom GT, Kwok WW. MHC class II tetramers identify peptide-specifi c human CD4(-) T cells proliferating in response to infl uenza A antigen. J Clin Invest. 1999;104:R63-7.
144. Douek DC, Betts MR, Brenchley JM, Hill BJ, Ambrozak DR, Ngai KL, et al. A novel approach to the analysis of specifi city, clonality, and frequency of HIV-specifi c T cell responses reveals a potential mechanism for control of viral escape. J Immunol. 2002;168:3099-104.
145. Price DA, West SM, Betts MR, Ruff LE, Brenchley JM, Ambrozak DR, et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity. 2004;21:793-803.
146. Scheinberg P, Melenhorst JJ, Hill BJ, Keyvanfar K, Barrett AJ, Price DA, et al. The clonal composition of human CD4- CD25- Foxp3- cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. J Immunol Methods. 2007;321:107-20.
147. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(-) T cell responses. J Exp Med. 2007;204:1405-16.
148. Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, et al. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4- T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res. 2009;15:4467-74.
149. Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, et al. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol. 2009;183:5397-406.
150. Derre L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A, et al. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci USA. 2008;105:15010-5.
151. Price DA, Asher TE, Wilson NA, Nason MC, Brenchley JM, Metzler IS, et al. Public clonotype usage identifi es protective Gag-specifi c CD8- T cell responses in SIV infection. J Exp Med. 2009;206:923-36.
152. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, et al. Direct access to CD4- T cells specifi c for defi ned antigens according to CD154 expression. Nat Med. 2005;11:1118-24.
153. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specifi c CD4- T cells with diverse cytokine profi les. Nat Med. 2005;11:1113-7.
154. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identifi cation of antigen-specifi c CD8- T cells by a fl ow cytometric assay for degranulation. J Immunol Methods. 2003;281: 65-78.
155. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al.
156. Heemskerk MH, de Paus RA, Lurvink EG, Koning F, Mulder A, Willemze R, et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci USA. 2001;98:6806-11.
157. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006;66:8878-86.
158. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfi de bond. Cancer Res. 2007;67:3898-903.
159. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, et al. Improved expression and reactivity of transduced tumor-specifi c TCRs in human lymphocytes by specifi c silencing of endogenous TCR. Cancer Res. 2009;69: 9003-11.
160. Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, Zhao Y, et al. Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infi ltrating lymphocytes. Hum Gene Ther. 2009;20:630-40.
161. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med. 2009;206:463-75.
162. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-9.
163. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114: 535-46.